Science Explorer Back to mapMap
Discussion
Institution · Pinnacle Clinical Research

Most cited papers from Pinnacle Clinical Research

Pinnacle Clinical Research

What are the most cited papers from Pinnacle Clinical Research?

The most cited paper from Pinnacle Clinical Research is "The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases" (Naga Chalasani, Zobair M. Younossi, Joel E. Lavine et al., 2017), with 7,419 citations. Next come "A Phase 3, Randomized, Controlled Trial of Resmetirom in NASH with Liver Fibrosis" (1,963) and "KRAS G12C Inhibition with Sotorasib in Advanced Solid Tumors" (1,743).

Showing 50 of 60 papers. Every paper with more than 196 citations is listed.

Most cited papers, sortable by citations and release date
#Paper
1 The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases Naga Chalasani, Zobair M. Younossi, Joel E. Lavine et al. · Hepatology Open access 17 Jul 2017 7,419
2 A Phase 3, Randomized, Controlled Trial of Resmetirom in NASH with Liver Fibrosis Stephen A. Harrison et al. · New England Journal of Medicine Open access 7 Feb 2024 1,963
3 KRAS G12C Inhibition with Sotorasib in Advanced Solid Tumors David S. Hong et al. · New England Journal of Medicine Open access 20 Sep 2020 1,743
4 Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial Zobair M. Younossi et al. · The Lancet Open access388 authors Dec 2019 1,260
5 Pulmonary Arterial Hypertension David B. Badesch, Gary E. Raskob, C. Gregory Elliott et al. · CHEST Journal 16 Oct 2009 1,187
6 Breast Cancer Screening Using Tomosynthesis in Combination With Digital Mammography Sarah M. Friedewald, Elizabeth A. Rafferty, Stephen L. Rose et al. · JAMA 24 Jun 2014 849
7 Resmetirom (MGL-3196) for the treatment of non-alcoholic steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial Stephen A. Harrison, Mustafa Rifaat Bashir, Cynthia D. Guy et al. · The Lancet Nov 2019 794
8 A Randomized, Controlled Trial of the Pan-PPAR Agonist Lanifibranor in NASH Sven Francque et al. · New England Journal of Medicine Open access 20 Oct 2021 778
9 The 2019 American College of Rheumatology/European League Against Rheumatism Classification Criteria for IgG4‐Related Disease Zachary Scott Wallace et al. · Arthritis & Rheumatology Open access 2 Dec 2019 684
10 A randomized, placebo‐controlled trial of cenicriviroc for treatment of nonalcoholic steatohepatitis with fibrosis Scott L. Friedman et al. · Hepatology Open access 17 Aug 2017 676
11 Predicting Survival in Patients With Pulmonary Arterial Hypertension Raymond L. Benza, Mardi Gomberg‐Maitland, C. Gregory Elliott et al. · CHEST Journal Open access 14 Feb 2019 648
12 Minimal Clinically Important Difference for the Ocular Surface Disease Index Kimberly Litwin Miller · Archives of Ophthalmology 2010 613
13 Pegbelfermin (BMS-986036), a PEGylated fibroblast growth factor 21 analogue, in patients with non-alcoholic steatohepatitis: a randomised, double-blind, placebo-controlled, phase 2a trial Arun Jayant Sanyal, Edgar D. Charles, Brent A. Neuschwander‐Tetri et al. · The Lancet Dec 2018 543
14 Rituximab in relapsing‐remitting multiple sclerosis: A 72‐week, open‐label, phase I trial Amit Bar‐Or, Peter A. Calabresi, Douglas Lorne Arnold et al. · Annals of Neurology Mar 2008 533
15 Five-Year Outcomes of Patients Enrolled in the REVEAL Registry Harrison W. Farber, Dave P. Miller, Abby D. Poms et al. · CHEST Journal Open access 11 Jun 2015 528
16 Randomized, Controlled Trial of the FGF21 Analogue Pegozafermin in NASH Rohit Seth Loomba, Arun Jayant Sanyal, Kris V. Kowdley et al. · New England Journal of Medicine Open access 24 Jun 2023 501
17 Selonsertib for patients with bridging fibrosis or compensated cirrhosis due to NASH: Results from randomized phase III STELLAR trials Stephen A. Harrison et al. · Journal of Hepatology 640 authors 5 Mar 2020 494
18 Outcome in systemic AL amyloidosis in relation to changes in concentration of circulating free immunoglobulin light chains following chemotherapy Helen Jane Lachmann, Ruth Gallimore, Julian David Gillmore et al. · British Journal of Haematology Open access 20 Jun 2003 436
19 Characterization of Connective Tissue Disease-Associated Pulmonary Arterial Hypertension From REVEAL Lorinda Chung, Juliana Liu, Lori S. Parsons et al. · CHEST Journal Open access 27 May 2010 434
20 Diagnostic modalities for nonalcoholic fatty liver disease, nonalcoholic steatohepatitis, and associated fibrosis Zobair M. Younossi et al. · Hepatology Open access 9 Dec 2017 433
21 Resmetirom for nonalcoholic fatty liver disease: a randomized, double-blind, placebo-controlled phase 3 trial Stephen A. Harrison, Rebecca A. Taub, Guy W. Neff et al. · Nature Medicine Open access 16 Oct 2023 428
22 From NAFLD to MAFLD: Implications of a Premature Change in Terminology Zobair M. Younossi, Mary Eugenia Rinella, Arun Jayant Sanyal et al. · Hepatology 16 Jun 2020 420
23 2-Year Outcomes in Patients Undergoing Surgical or Self-Expanding Transcatheter Aortic Valve Replacement Michael J. Reardon et al. · Journal of the American College of Cardiology Open access 5 Jun 2015 409
24 The Natural History of Advanced Fibrosis Due to Nonalcoholic Steatohepatitis: Data From the Simtuzumab Trials Arun Jayant Sanyal, Stephen A. Harrison, Vlad Ratziu et al. · Hepatology 17 Apr 2019 396
25 Symptoms and treatment burden associated with cancer treatment: results from a cross-sectional national survey in the U.S. David H. Henry, Hema N. Viswanathan, Eric P. Elkin et al. · Supportive Care in Cancer 16 Jan 2008 391
26 Simtuzumab Is Ineffective for Patients With Bridging Fibrosis or Compensated Cirrhosis Caused by Nonalcoholic Steatohepatitis Stephen A. Harrison et al. · Gastroenterology 7 Jul 2018 387
27 Randomized Phase II Study of Erlotinib Plus Tivantinib Versus Erlotinib Plus Placebo in Previously Treated Non–Small-Cell Lung Cancer Lecia Van Dam Sequist, Joachim von Pawel, Edward Graeme Garmey et al. · Journal of Clinical Oncology 19 Jul 2011 380
28 Cenicriviroc Treatment for Adults With Nonalcoholic Steatohepatitis and Fibrosis: Final Analysis of the Phase 2b CENTAUR Study Vlad Ratziu, Arun Jayant Sanyal, Stephen A. Harrison et al. · Hepatology Open access 13 Jan 2020 377
29 Current and future therapeutic regimens for nonalcoholic fatty liver disease and nonalcoholic steatohepatitis Zobair M. Younossi et al. · Hepatology Open access 9 Dec 2017 366
30 Efruxifermin in non-alcoholic steatohepatitis: a randomized, double-blind, placebo-controlled, phase 2a trial Stephen A. Harrison, Peter Jerome Ruane, Bradley L. Freilich et al. · Nature Medicine Jul 2021 363
31 Challenges and opportunities in NASH drug development Stephen A. Harrison, Alina M. Allen, Julie Dubourg et al. · Nature Medicine Mar 2023 361
32 Effects of Belapectin, an Inhibitor of Galectin-3, in Patients With Nonalcoholic Steatohepatitis With Cirrhosis and Portal Hypertension Naga Chalasani et al. · Gastroenterology Open access 5 Dec 2019 357
33 The Changing Picture of Patients With Pulmonary Arterial Hypertension in the United States Adaani Frost, David B. Badesch, Robyn J. Barst et al. · CHEST Journal 17 Jun 2010 355
34 Assessing Improvement in Detection of Breast Cancer with Three-dimensional Automated Breast US in Women with Dense Breast Tissue: The SomoInsight Study Rachel F. Brem, László K. Tabár, Stephen William Duffy et al. · Radiology 20 Oct 2014 355
35 GS-0976 Reduces Hepatic Steatosis and Fibrosis Markers in Patients With Nonalcoholic Fatty Liver Disease Rohit Seth Loomba, Zeid Kayali, Mazen Noureddin et al. · Gastroenterology Open access 27 Jul 2018 340
36 Cilofexor, a Nonsteroidal FXR Agonist, in Patients With Noncirrhotic NASH: A Phase 2 Randomized Controlled Trial Keyur Patel et al. · Hepatology 2 Mar 2020 336
37 Epidemiology, clinical and economic outcomes of admission hyponatremia among hospitalized patients Marya D. Zilberberg, Alex Exuzides, James Robert Spalding et al. · Current Medical Research and Opinion 17 Apr 2008 328
38 Delay in Recognition of Pulmonary Arterial Hypertension Lynette M. Brown, Hubert Chen, Scott D. Halpern et al. · CHEST Journal Open access 10 Mar 2011 296
39 Combination Therapies Including Cilofexor and Firsocostat for Bridging Fibrosis and Cirrhosis Attributable to NASH Rohit Seth Loomba et al. · Hepatology 10 Nov 2020 290
40 Assessment of safety and efficacy of long-term treatment with combination lumacaftor and ivacaftor therapy in patients with cystic fibrosis homozygous for the F508del-CFTR mutation (PROGRESS): a phase 3, extension study Michael W. Konstan, Edward F. McKone, Richard B. Moss et al. · The Lancet Respiratory Medicine 21 Dec 2016 289
41 Serum test for assessment of patients with Bence Jones myeloma Arthur R. Bradwell, Hugh D Carr-Smith, Graham Peter Mead et al. · The Lancet Feb 2003 286
42 Eculizumab in Pregnant Patients with Paroxysmal Nocturnal Hemoglobinuria Richard J. Kelly, Britta Höchsmann, Jeff Szer et al. · New England Journal of Medicine Open access 10 Sep 2015 283
43 Noninvasive Tests Accurately Identify Advanced Fibrosis due to NASH: Baseline Data From the STELLAR Trials Quentin Mark Anstee et al. · Hepatology 4 Jul 2019 276
44 Efficacy and Safety of Aldafermin, an Engineered FGF19 Analog, in a Randomized, Double-Blind, Placebo-Controlled Trial of Patients With Nonalcoholic Steatohepatitis Stephen A. Harrison, Guy W. Neff, Cynthia D. Guy et al. · Gastroenterology Open access 8 Aug 2020 271
45 Safety and efficacy of once-weekly efruxifermin versus placebo in non-alcoholic steatohepatitis (HARMONY): a multicentre, randomised, double-blind, placebo-controlled, phase 2b trial Stephen A. Harrison, Juan P. Frías, Guy W. Neff et al. · ˜The œLancet. Gastroenterology & hepatology 3 Oct 2023 266
46 A randomized, placebo-controlled trial of emricasan in patients with NASH and F1-F3 fibrosis Stephen A. Harrison, Zachary D Goodman, Abdul Jabbar et al. · Journal of Hepatology 27 Dec 2019 260
47 NGM282 Improves Liver Fibrosis and Histology in 12 Weeks in Patients With Nonalcoholic Steatohepatitis Stephen A. Harrison, Stephen J. Rossi, Angelo H. Paredes et al. · Hepatology Open access 26 Feb 2019 260
48 A blood-based biomarker panel (NIS4) for non-invasive diagnosis of non-alcoholic steatohepatitis and liver fibrosis: a prospective derivation and global validation study Stephen A. Harrison et al. · ˜The œLancet. Gastroenterology & hepatology 4 Aug 2020 254
49 Sustained Benefit from Ivacaftor Demonstrated by Combining Clinical Trial and Cystic Fibrosis Patient Registry Data Gregory S. Sawicki, Edward F. McKone, David J. Pasta et al. · American Journal of Respiratory and Critical Care Medicine Jul 2015 241
50 Sifalimumab, a Human Anti–Interferon‐α Monoclonal Antibody, in Systemic Lupus Erythematosus: A Phase I Randomized, Controlled, Dose‐Escalation Study Michelle Petri, Daniel J. Wallace, Alberto J. Spindler et al. · Arthritis & Rheumatism Open access 11 Feb 2013 241

Citations are OpenAlex's own counts, from its 2026-09-23 snapshot, so the ranking can differ from Google Scholar or Web of Science. A paper is listed for an institution when any of its authors gave it as an affiliation; retracted papers and papers whose citation count cannot be traced to citing works are left out, and a preprint and the article it became are shown once. Release dates are OpenAlex's: where a source gave only a month or a year, that is what is shown. How the lists are chosen.